Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1

Status

Recruiting 10Active not recruiting 6Not yet recruiting 3

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 6Recurrence 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 194pembrolizumab 185Carboplatin 160Biopsy 129Cisplatin 128Nivolumab 119Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 96Dexamethasone 86durvalumab 83atezolizumab 70Rituximab 66Radiation 64Lenalidomide 64Doxorubicin 63Pemetrexed 61Bevacizumab 58Etoposide 56Docetaxel 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 46Vincristine 45Cytarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × iberdomide × 90 days × Clear all
NCT05434689 2026-06-01

COMMANDER

University of Alabama at Birmingham

Phase 1/2 Active not recruiting
80 enrolled
Plasma cell

Multiple Myeloma

NCT05354557 2026-05-18

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
16 enrolled
Plasma cell

Multiple Myeloma

NCT05527340 2026-05-08

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

PETHEMA Foundation

Phase 2 Active not recruiting
140 enrolled
Plasma cell

Multiple Myeloma

NCT05392946 2026-04-21

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Mayo Clinic

Phase 1/2 Active not recruiting
49 enrolled
Plasma cell

Multiple Myeloma

NCT04975997 2026-04-03

EXCALIBER-RRMM

Celgene

Phase 3 Active not recruiting
939 enrolled
Plasma cell

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Celgene

Phase 1/2 Active not recruiting
466 enrolled 57 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡